Main Uses and Benefits of Berotec N 100

Berotec N 100 (Fenoterol hydrobromide) is a short-term supportive agent commonly used to help manage symptoms related to acute, reversible airway narrowing. Its use is relevant across domains where short-term symptomatic assistance for obstructive airway diseases is appropriate.

This medication is considered relevant for the symptomatic relief of conditions characterized by periods of heightened symptoms, specifically bronchial asthma, the reversible elements of Chronic Obstructive Pulmonary Disease (COPD), and the predictive prevention of exercise-induced asthma. Applied when supportive symptom management is appropriate, it contributes to easing the overall symptom load during episodes of distress.

Quick Relief for Acute Respiratory Distress

The medication is used for supportive relief of symptoms that interfere with daily functioning, such as pronounced shortness of breath, discomforting chest tightness, and wheezing, which are symptoms related to physical discomfort. Applied in clinical settings that involve acute or unstable symptom patterns, it may assist with maintaining functional stability when symptoms are more noticeable.

“This agent is used in situations involving certain distressing symptoms when short-term assistance is appropriate.”

Quick Fact: Relief for Acute Airflow Restriction
This medication supports individuals during acute episodes by focusing on the symptomatic relief of shortness of breath and wheezing.

Who Can and Cannot Use Berotec N 100? — Official Regulatory Information

The following information outlines the official eligibility and non-eligibility for Berotec N 100 (fenoterol hydrobromide) as defined in regulatory documents. This medicine is available by physician prescription only.

Eligibility Status	Specific Populations/Conditions
Contraindicated	Patients with hypertrophic obstructive cardiomyopathy or tachyarrhythmia (abnormally fast heart rhythm). Also, patients with known hypersensitivity to fenoterol hydrobromide or any of the product's excipients.
Use Requires Careful Assessment	Patients with insufficiently controlled diabetes mellitus, recent myocardial infarction, severe organic heart or vascular disorders, hyperthyroidism, or phaeochromocytoma. Highest recommended doses must be used with particular caution.
Age-Related Rules	Generally for adults and children over 6 years of age. Use in children requires medical advice and adult supervision.
Pregnancy/Lactation	Pregnancy: Use requires the usual precautions, especially in the first trimester, and the inhibitory effect on uterine contractions should be considered. Lactation: Fenoterol is excreted into breastmilk, and safety during breastfeeding has not been established; caution is required.

---

The regulatory labeling clearly identifies specific cardiac conditions and hypersensitivity as absolute contraindications for use. For other serious coexisting disorders, such as severe cardiovascular disease, uncontrolled diabetes, and thyroid conditions, the official guidance requires a careful risk/benefit assessment by a healthcare provider prior to and during treatment. Pediatric use is permitted only under medical guidance and supervision.

Berotec N 100 (fenoterol) is a sympathomimetic agent whose activity may be affected by or combined with other medications, potentially leading to altered therapeutic effects or an increased risk of side effects.

Concomitant Use with Increased Risk of Side Effects:

The concurrent use of Berotec N 100 with other beta-adrenergic receptor stimulants, oral anticholinergics, or xanthine derivatives (such as theophylline) may result in an additive effect, increasing the likelihood or severity of side effects.

Risk of Severe Hypokalemia and Arrhythmias:

Caution is required when co-administering Berotec N 100 with corticosteroids, diuretics, or xanthine derivatives. This combination can lead to an additive, potentially serious, decrease in serum potassium levels (hypokalemia). This electrolyte imbalance is particularly concerning for patients taking digoxin, as it increases the risk of heart rhythm disorders (arrhythmias).

Impact on Efficacy and Cardiovascular System:

• Beta-adrenergic receptor blockers (beta-blockers) may substantially diminish or antagonize the bronchodilatory effects of fenoterol.
• Certain antidepressants, including Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants, can enhance the effect of fenoterol on the cardiovascular system, necessitating careful use.
• Inhalation of halogenated general anesthetics (e.g., halothane, trichloroethylene, enflurane) can increase the heart's susceptibility to the cardiovascular effects of beta-agonists like fenoterol, potentially causing irregular heartbeats.

Targeting the Beta-2 Adrenergic Receptor

The active ingredient, fenoterol, initiates its action by functioning as a selective agonist on the beta-2 adrenergic receptors (beta2 AR). These receptors are densely distributed on the smooth muscle cells surrounding the bronchial passages in the lungs. Receptor binding triggers an intracellular G-protein signaling cascade that is the necessary first step toward modulating muscle tension.

Cellular Signal and Airway Muscle Relaxation

Activation of the beta2 AR stimulates the adenylyl cyclase enzyme, resulting in a rapid increase of the second messenger, cyclic AMP (cAMP), within the muscle cell. Elevated cAMP levels activate Protein Kinase A (PKA), which subsequently limits the intracellular calcium availability and inhibits the cellular processes required for muscle contraction. This cascade contributes to the relaxation of the bronchial smooth muscle tissue.

Resulting Physiological Effect: Airflow Modulation

This targeted relaxation of the muscle tissue results in an increase in the lumen diameter of the airways, a process termed bronchodilation. This action modulates the resistance to airflow through the bronchial passages, thereby influencing pulmonary airflow patterns.

How Berotec N 100 is Used: Administration Guidelines

Berotec N 100 (Fenoterol hydrobromide) is designed for use as an intermittent, on-demand intervention to be delivered exclusively by the inhalation route via the Metered Dose Inhaler (MDI). The device provides a specific dose of 100 micrograms per actuation.

---

Administration Scope

The frequency pattern is as-needed (PRN) for acute events or preemptively for prophylaxis, defining its role as a short-term supportive agent.

Usage Context	Standard Labeled Dosing	Maximum Limit per Day
Acute Symptom Relief	1 puff initially; a second dose may be administered after 5 minutes if breathing has not noticeably improved.	8 puffs per day should generally not be exceeded for routine, intermittent use.
Prophylaxis (Pre-exercise)	1 to 2 puffs are administered prior to exercise.

Age-Group Administration Rules: Use in children requires medical advice and adult supervision. The recommended dose for children aged 4–6 years is generally 1 puff for acute symptoms or prophylaxis.

Special Procedural Conditions: Prior to initial use, the inhaler must be primed (actuated twice); if not used for three days, it must be actuated once before use. To ensure proper delivery, the patient is instructed to gargle with water or rinse the mouth after inhalation. The device must be replaced after the labeled 200 actuations have been used.

---

Connection to the Overall Use Protocol

These instructions establish a precise, non-scheduled protocol for administering the drug, ensuring that the 100 micrograms dose is reliably delivered via the specific MDI device only when required for time-bound events. The explicit maximum dose limit and the mandatory device preparation steps govern the safe and accurate amount of drug that should be delivered.

Research Evidence / Overview of Studies for Berotec N 100

Evidence for Use in Acute Symptoms of Bronchial Asthma

Research for Fenoterol hydrobromide includes short-term Randomized Controlled Trials (RCTs) and systematic reviews focusing on adults, adolescents, and children with reversible airflow obstruction. Studies monitored changes in lung function, such as the Forced Expiratory Volume in 1 second ( FEV1), a measure of lung function. Findings describe patterns observed over short time intervals. Long-term effects, including overall control and tolerance with regular use, are not fully established. Evidence for use beyond a few weeks remains insufficient.

---

Evidence for Use in Reversible Elements of COPD

Research examined Fenoterol in the context of Chronic Obstructive Pulmonary Disease (COPD) with reversible airway narrowing. Studies, including RCTs, evaluated short-term symptom changes and tracked lung function measures like FEV1 and FVC, measures of breathing capacity. When Fenoterol was evaluated as part of a combination product, data for the specific contribution of the Fenoterol component remains uncertain. Follow-up durations were limited, and long-term effects on major clinical outcomes like disease progression are not clearly established.

---

Evidence for the Predictive Prevention of Exercise-Induced Bronchospasm

The research for Exercise-Induced Bronchospasm (EIB) is largely derived from specialized acute challenge studies. These studies, involving children and adolescents, examined outcomes related to changes in lung function after a standardized exercise challenge. Research highlights changes measured during the study period, with some studies describing patterns related to a less pronounced decline in FEV1. The evidence is predominantly derived from single-dose activity, and data on repeated, high-frequency use for prevention remain insufficient.

---

Long-Term Follow-up, Special Populations, and Uncertainty

Most available evidence is derived from trials with limited follow-up durations, typically hours or short-term periods up to 12 weeks. Research has explored use in specific groups, including children, adolescents, and older adults; however, findings for complex subgroups are often uncertain. A key area where certainty remains low is the assessment of long-term safety and effectiveness when Fenoterol is used frequently. This is a common research limitation regarding short-acting bronchodilators.

Common questions about Berotec N 100 (FAQ)

Q: What types of breathing problems is Berotec N 100 typically prescribed for?

The official product information indicates that Berotec N 100 is prescribed for the symptomatic treatment of conditions that cause reversible airway narrowing, such as bronchial asthma and chronic bronchitis.

Its core purpose is to provide relief by opening the air passages.

Q: How quickly does Berotec N 100 usually start working?

Berotec N 100 is a rapid-acting bronchodilator intended for use during acute breathing difficulties. Official product information notes that its effects generally begin shortly after inhalation, often within minutes.

Q: How long does the bronchodilating effect of Berotec N 100 last?

According to regulatory pharmacokinetic properties, the intended bronchodilating effect of the medicine typically lasts for approximately 3 to 6 hours following administration. This duration defines its role as a short-term, on-demand rescue agent.

Q: Are there known side effects related to sleep when using Berotec N 100?

While regulatory documents may not explicitly list insomnia as a side effect, the official label does note common central nervous system effects such as nervousness and agitation.

These effects are recognized as potentially interfering with normal sleep patterns.

Q: Are there known interactions between Berotec N 100 and high blood pressure medications?

Yes, regulatory documents describe several potential drug interactions. Specifically, Beta-adrenergic receptor blockers (beta-blockers), which are used for high blood pressure, may reduce the bronchodilating effect of Berotec N 100. Other medications, including certain types of antidepressants, can enhance the drug's effect on the cardiovascular system.

Q: What is the research evidence for using Berotec N 100 during pregnancy?

Official information describes that the use of Berotec N 100 during pregnancy is a matter of caution, particularly during the first three months. Regulatory documents also note that the inhibitory effect of the drug on uterine contractions is a factor for consideration by a healthcare professional.

Q: What are the differences between Fenoterol (the ingredient in Berotec) and Salbutamol (Albuterol)?

Both Fenoterol (the active ingredient in Berotec N 100) and Salbutamol (also known as Albuterol) are classified as short-acting beta-agonists (SABAs). Pharmacological data indicates Fenoterol may exhibit greater systemic potency at microgram-equivalent doses. This difference in potency is understood to carry a risk of stronger systemic effects, such as increased tremor or heart rate, relative to some other SABAs.

Q: Why did the formulation of the Berotec N 100 inhaler change to CFC-free?

The change from using Chlorofluorocarbon (CFC) propellant to the current Hydrofluoroalkane (HFA) propellant was based on a global environmental mandate. This regulation required pharmaceutical companies to phase out CFCs because they are ozone-depleting substances.

Q: Does the CFC-free version of Berotec N 100 taste or feel different?

Official documentation notes that HFA formulations may contain a small amount of ethanol (alcohol) or other excipients.

This difference in composition may result in a slightly different taste or the sensation of a warm, pungent feeling in the mouth or throat upon inhalation compared to older formulations.

Q: Is there a distinction between Berotec N 100 and Berodual?

Yes, there is a clear distinction in their composition. Berotec N 100 contains Fenoterol as a single active ingredient (a bronchodilator).

Berodual is a combination product that contains both Fenoterol and a second active ingredient, Ipratropium bromide, which acts as an anticholinergic.

Q: What should be done if the Berotec N 100 inhaler appears to be empty?

The official instructions indicate that the device life is set by the labeled number of doses (typically 200 actuations). The product information states the device is intended for replacement after the designated number of actuations is reached, irrespective of visual appearance.

Q: Can Berotec N 100 affect the ability to drive or operate machinery?

Yes. Regulatory information notes that due to potential side effects like dizziness, tremor, or nervousness, impairment of abilities that require mental alertness, such as driving or operating heavy machinery, may occur.

Q: What is the expected duration of treatment with Berotec N 100?

Regulatory guidance describes Berotec N 100 as an intermittent, on-demand intervention for acute symptoms. It is not intended for continuous, long-term, daily maintenance therapy, but rather as a short-term supportive agent to be used only as needed.

Q: What is the function of the propellant or non-active ingredients in the inhaler?

The non-active ingredients, including the Hydrofluoroalkane (HFA) propellant, are crucial for the medicine's function. They are necessary to create the fine aerosol mist and carry the precise 100 micrograms dose, ensuring it is delivered effectively to the bronchial airways.

Q: Is it possible to use a spacer device with the Berotec N 100 inhaler?

Metered Dose Inhalers (MDIs), like Berotec N 100, are generally compatible with spacer devices. Official regulatory guidance indicates that using a spacer may be considered to help improve delivery and potentially reduce local side effects in the mouth and throat.

Q: What is the history of the research and development of Fenoterol?

Fenoterol was initially patented in 1962 and was subsequently introduced for medical use starting in 1971. Since its introduction, its use and safety profile have been subject to ongoing review and monitoring by government regulatory bodies.

Q: What is the general evidence regarding the use of Berotec N 100 in sport or physical activity?

Research evidence supports the use of Berotec N 100 for the prophylactic prevention of a condition known as exercise-induced bronchospasm (EIB). Official administration guidelines include a protocol for administering the medicine prior to engaging in physical activity.

Q: What are the differences in effects between the aerosol and nebulizer solution forms of Fenoterol?

The MDI aerosol form is intended for portable, acute relief and is dosed in micrograms (mu g). The nebulizer solution form is typically dosed in milligrams ( mg) and often used in clinical settings for severe acute attacks.

Q: Is there information on the safety profile of Berotec N 100 compared to other SABAs?

While regulatory documents do not offer direct brand-to-brand comparative recommendations, the safety profile of Fenoterol is pharmacologically understood. Its systemic effects are noted to carry a risk of greater systemic effects, such as increased tremor and heart rate, relative to some other SABAs, a fact established through research and regulatory review.

How to Store and Dispose of Berotec N 100?

Storage Requirements

The pressurized canister must be stored away from heat, moisture, and direct sunlight. Official labeling requires that the product must not be exposed to temperatures exceeding 50 C. The canister must not be forcibly opened, punctured, or incinerated. After each use, the protective cap must be replaced to protect the mouthpiece. This medication must be stored out of the reach and sight of children.

Handling and Disposal Instructions

It is required to use only the specific mouthpiece supplied with the Berotec N 100 product. Unused or expired medicine must be discarded according to established regulatory guidelines. Due to its pressurized nature, the canister must be disposed of according to local regulations for pharmaceutical waste or pressurized vessels. The product must not be flushed into the surface water or sanitary sewer system.